Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allison F Wagner

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of American College Health : J of ACH|March 26, 2019
Examining the impact of social media on mood and body dissatisfaction using ecological momentary assessmentBrooke L Bennett, Brooke L Whisenhunt, Danae L Hudson, et al.
Neurobiology of Aging|July 15, 2018
Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trialNicole M Barcelos, Peter H Van Ness, Allison F Wagner, et al.
Alzheimer'S Research & Therapy|April 16, 2015
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's diseaseHaakon B Nygaard, Allison F Wagner, Garrett S Bowen, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of American College Health : J of ACH|March 26, 2019
Examining the impact of social media on mood and body dissatisfaction using ecological momentary assessmentBrooke L Bennett, Brooke L Whisenhunt, Danae L Hudson, et al.
Neurobiology of Aging|July 15, 2018
Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trialNicole M Barcelos, Peter H Van Ness, Allison F Wagner, et al.
Alzheimer'S Research & Therapy|April 16, 2015
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's diseaseHaakon B Nygaard, Allison F Wagner, Garrett S Bowen, et al.
Pageof 2